X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (143) 143
female (136) 136
oncology (124) 124
breast neoplasms - drug therapy (90) 90
middle aged (86) 86
breast cancer (80) 80
breast neoplasms - pathology (80) 80
index medicus (79) 79
chemotherapy, adjuvant (65) 65
breast neoplasms - surgery (64) 64
chemotherapy (53) 53
cancer (50) 50
antineoplastic combined chemotherapy protocols - therapeutic use (48) 48
surgery (47) 47
adult (42) 42
aged (42) 42
prognosis (37) 37
disease-free survival (34) 34
treatment outcome (34) 34
breast neoplasms - mortality (32) 32
neoplasm staging (32) 32
tamoxifen (31) 31
surgical adjuvant breast (30) 30
cyclophosphamide - administration & dosage (29) 29
doxorubicin - administration & dosage (28) 28
neoadjuvant therapy (27) 27
article (26) 26
antineoplastic agents, hormonal - therapeutic use (25) 25
follow-up studies (25) 25
mastectomy, segmental (25) 25
adjuvant treatment (24) 24
breast neoplasms - therapy (24) 24
combined modality therapy (24) 24
lymphatic metastasis (24) 24
randomized controlled trials as topic (24) 24
survival analysis (24) 24
tamoxifen - therapeutic use (24) 24
women (24) 24
mastectomy (23) 23
medicine & public health (23) 23
preoperative chemotherapy (22) 22
breast neoplasms - radiotherapy (21) 21
clinical trials (21) 21
radiation-therapy (21) 21
therapy (21) 21
trastuzumab (21) 21
care and treatment (19) 19
radiotherapy (19) 19
lumpectomy (18) 18
risk factors (17) 17
sentinel lymph node biopsy (17) 17
survival rate (17) 17
trial (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
cancer therapies (16) 16
randomized-trial (16) 16
biopsy (15) 15
carcinoma (15) 15
original reports (15) 15
receptors, estrogen - analysis (15) 15
taxoids - administration & dosage (15) 15
time factors (15) 15
antineoplastic agents - therapeutic use (14) 14
hematology, oncology and palliative medicine (14) 14
neoadjuvant chemotherapy (14) 14
paclitaxel - administration & dosage (14) 14
surgical oncology (14) 14
breast neoplasms - chemistry (13) 13
clinical trials as topic (13) 13
health aspects (13) 13
prospective studies (13) 13
research (13) 13
survival (13) 13
breast neoplasms - genetics (12) 12
docetaxel (12) 12
drug administration schedule (12) 12
drug therapy (12) 12
neoplasm recurrence, local - pathology (12) 12
radiotherapy, adjuvant (12) 12
risk (12) 12
cyclophosphamide (11) 11
local recurrence (11) 11
medicine, general & internal (11) 11
neoplasm recurrence, local (11) 11
patient outcomes (11) 11
postmenopausal women (11) 11
proportional hazards models (11) 11
tumors (11) 11
20-year follow-up (10) 10
bc5 (10) 10
doxorubicin (10) 10
male (10) 10
medical colleges (10) 10
metastases (10) 10
paclitaxel (10) 10
radiation therapy (10) 10
receptors, estrogen - metabolism (10) 10
risk assessment (10) 10
tamoxifen - administration & dosage (10) 10
abridged index medicus (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 05/2015, Volume 22, Issue 5, pp. 1425 - 1433
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 8/2018, Volume 25, Issue 8, pp. 2124 - 2126
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1245/s10434-018-6537-z 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | BREAST-CANCER | TRIAL | SURGERY | NODE BIOPSY | ONCOLOGY | DISSECTION | METASTASES | Breast Neoplasms - surgery | Breast Neoplasms - pathology | Humans | Axilla | Female | Neoadjuvant Therapy | Sentinel Lymph Node Biopsy | Lymph Node Excision - standards | Breast Neoplasms - drug therapy | Adjuvant treatment | Cancer
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 10, pp. 927 - 933
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10021, pp. 849 - 856
Summary Background Ductal carcinoma in situ is currently managed with excision, radiotherapy, and adjuvant hormone therapy, usually tamoxifen. We postulated... 
Internal Medicine | INTRADUCTAL BREAST-CANCER | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | RADIATION-THERAPY | B-17 | Breast Neoplasms - surgery | Triazoles - administration & dosage | Triazoles - adverse effects | Thrombosis - chemically induced | Age Factors | Humans | Middle Aged | Tamoxifen - administration & dosage | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Aromatase Inhibitors - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Mastectomy, Segmental | Antineoplastic Agents, Hormonal - therapeutic use | Postmenopause | Female | Embolism - chemically induced | Aromatase Inhibitors - therapeutic use | Triazoles - therapeutic use | Aromatase Inhibitors - administration & dosage | Carcinoma, Ductal, Breast - surgery | Double-Blind Method | Administration, Oral | Antineoplastic Agents, Hormonal - administration & dosage | Combined Modality Therapy | Breast Neoplasms - drug therapy | Breast Neoplasms - radiotherapy | Carcinoma, Ductal, Breast - radiotherapy | Tamoxifen - therapeutic use | Tamoxifen - adverse effects | Nitriles - adverse effects | Nitriles - therapeutic use | Lumpectomy | Medical colleges | Carcinoma | Radiation | Clinical trials | Postmenopausal women | Hormones | Tamoxifen | Radiotherapy | Biometry | Health maintenance organizations | Product development | Cancer | Chemotherapy | Womens health | Older people | Breast cancer | Radiation therapy | Cancer surgery
Journal Article
The breast journal, ISSN 1075-122X, 06/2019
Metaplastic breast carcinoma (MBC) is a rare subtype of invasive breast cancer consisting of various combinations of malignant epithelial and mesenchymal... 
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2010, Volume 362, Issue 22, pp. 2053 - 2065
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article